Lasa Supergenerics Ltd. (IN:LASA)
:LASA
LASA Stock Chart & Stats
₹11.33
-₹1.79(-6.22%)
At close: 4:00 PM EST
₹11.33
-₹1.79(-6.22%)
Day’s Range― - ―
52-Week Range₹5.65 - ₹19.65
Previous CloseN/A
Volume56.48K
Average Volume (3M)39.13K
Market Cap
₹313.13M
Enterprise Value₹383.13M
Total Cash (Recent Filing)₹6.96M
Total Debt (Recent Filing)₹73.38M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Jun 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding50,101,240
10 Day Avg. Volume9,122
30 Day Avg. Volume39,131
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.08
Price to Sales (P/S)0.63
P/FCF Ratio-32.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
B2B API Manufacturing ModelLasa's core business is manufacturing APIs for other drugmakers, a durable B2B model with recurring order potential and long-term supply contracts. This specialization supports steady industrial demand and stable unit-level revenues versus consumer-facing cyclicality over months.
Manageable LeverageA moderate debt-to-equity profile and relatively strong equity ratio preserve balance sheet flexibility, reducing short-term default risk and enabling the company to access credit or refinance if needed while addressing operational turnaround tasks over the coming months.
Lean Operations (small Headcount)A small workforce implies lower fixed labor overhead and operational agility. That lean cost base allows faster cost-control measures, quicker product-mix shifts, and enables management to align capacity to demand trends, aiding cash preservation during recovery periods.
Bears Say
Sharp Revenue DeclineNear-50% revenue contraction is a structural strain: loss of scale increases per-unit costs, weakens negotiating power with suppliers/customers, and makes it harder to cover fixed costs. Restoring volumes will take sustained commercial recovery and may require investment or pricing shifts.
Negative Margins And LossesPersistently negative gross and net margins indicate the business is not generating operating profitability. Continued losses erode equity, limit reinvestment in capacity or quality, and force reliance on external funding, constraining medium-term competitiveness and strategic initiatives.
Negative Operating And Free Cash FlowNegative operating and free cash flow restrict the firm's ability to fund working capital, maintain plants, or invest in product development without external capital. Continued cash deficits can lead to higher financing costs or dilution, hampering long-term recovery prospects.
Lasa Supergenerics Ltd. News
LASA FAQ
What was Lasa Supergenerics Ltd.’s price range in the past 12 months?
Lasa Supergenerics Ltd. lowest stock price was ₹5.65 and its highest was ₹19.65 in the past 12 months.
What is Lasa Supergenerics Ltd.’s market cap?
Lasa Supergenerics Ltd.’s market cap is ₹313.13M.
When is Lasa Supergenerics Ltd.’s upcoming earnings report date?
Lasa Supergenerics Ltd.’s upcoming earnings report date is Jun 01, 2026 which is in 56 days.
How were Lasa Supergenerics Ltd.’s earnings last quarter?
Lasa Supergenerics Ltd. released its earnings results on Feb 13, 2026. The company reported -₹0.51 earnings per share for the quarter, missing the consensus estimate of N/A by -₹0.51.
Is Lasa Supergenerics Ltd. overvalued?
According to Wall Street analysts Lasa Supergenerics Ltd.’s price is currently Overvalued.
Does Lasa Supergenerics Ltd. pay dividends?
Lasa Supergenerics Ltd. pays a Annually dividend of ₹0.25 which represents an annual dividend yield of N/A. See more information on Lasa Supergenerics Ltd. dividends here
What is Lasa Supergenerics Ltd.’s EPS estimate?
Lasa Supergenerics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lasa Supergenerics Ltd. have?
Lasa Supergenerics Ltd. has 50,101,240 shares outstanding.
What happened to Lasa Supergenerics Ltd.’s price movement after its last earnings report?
Lasa Supergenerics Ltd. reported an EPS of -₹0.51 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.032%.
Which hedge fund is a major shareholder of Lasa Supergenerics Ltd.?
Currently, no hedge funds are holding shares in IN:LASA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lasa Supergenerics Ltd.
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products primarily in India. It offers veterinary and other API products, anthelmintic products, animal feed ingredients, and reagents for therapeutic use. The company also exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Mumbai, India.
Technical Analysis
Aarey Drugs & Pharmaceuticals Ltd.
―
Balaxi Pharmaceuticals Limited
―
Bal Pharma Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
―